Battulga Bat 🧩’s Post

Tempus AI sold 11.1 million shares at the #top 🚀 of the range for $37 each; after offering them for $35 to $37. At the IPO price, the company has a market value of $6.1 billion. Founded in 2015, Tempus is creating an intelligent diagnostics platform for precision medicine ⚕. Positive news for #AI ; #digitalization and #data companies in healthcare that this IPO went through - at top of range pricing. The journey ahead won't be linear, but looking forward what's come. https://lnkd.in/eudTHqkC

As we begin to incorporate GenAI into clinical trial execution, IQVIA has developed a blueprint to ensure its success. From defining core principles governing the use of GenAI, to maximizing validation through diligent engineering, safeguards and continuous improvement, this white paper provides the four sequential steps to GenAI optimization. Download now. https://bit.ly/49lxS0W #GenAI #clinicaltrials

Discover the expected and unexpected benefits of AI-enabled site selection. From improved recruitment rates to faster study startup timelines, learn how ICON’s One Search AI is driving positive outcomes in clinical trials. https://ow.ly/lXr750R3UBF #HealthTech #AIAdvancements #ClinicalInnovation

Tempus AI, a health-care diagnostics company that uses AI to interpret medical tests to help physicians provide more accurate treatment for their patients, rose by as much as 15% in its Nasdaq Stock Market debut on Friday, after going public under the ticker symbol “TEM.” Tempus AI priced 11.1 million shares at $37 apiece on Thursday, at the top of its initial $35 to $37 target range. The company raised $410 million at an implied valuation of just over $6 billion. Its early gains took the company to a valuation as high as $7 billion, but it closed its first day of trading up nearly 9%, for a market cap of roughly $6.65 billion. #tempus #AI #Health #Nasdaq

Tempus AI Files for IPO, Eyes Over $600M in Funding for AI-Powered Precision Medicine - HIT Consultant #TempusAI #IPO #PrecisionMedicine #Funding Tempus AI, a leader in AI-powered precision medicine, has filed for an IPO with plans to raise over $600 million in funding. The company's innovative technology has the potential to revolutionize healthcare IT, offering advanced solutions for personalized treatment plans and improved patient outcomes. #AI-Powered Precision Medicine Tempus AI's cutting-edge technology leverages artificial intelligence to analyze vast amounts of patient data and genetic information, allowing healthcare providers to tailor treatment plans to individual patients. This approach to precision medicine has the potential to significantly enhance the quality of care and improve patient outcomes. #Benefits of AI in Healthcare The use of AI in healthcare has numerous benefits, including improved diagnostic accuracy ai.mediformatica.com #tempus #this #medicine #precisionmedicine #intelligence #revenue #artificialintelligence #chicago #illinois #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3yz0DdV)

Good to see an #IPO in the DX space with Tempus AI. With 11M shares at $37 per share at #top 🚀 end of the expected range, raising $410M at a valuation of $6B Founded in 2015, Tempus is creating an intelligent diagnostics platform for precision medicine ⚕. #Positive #news Looking forward what's come. #AI #healthcare #data #digitalization #DX https://lnkd.in/dJiKrrPC

Transforming Clinical Trials with AI: DST Technology’s Game Changer Pawan Agrawal On this International Clinical Trial Day, let's envision a future where innovation and efficiency revolutionize drug development. DST Technology's AI Accelerator stands at the forefront of this transformation, propelling preclinical and clinical workups into a new era of precision, speed, and cost-effectiveness. Imagine reducing the time and cost of clinical trials by leveraging the power of artificial intelligence. Our AI Accelerator optimizes data analysis, enhances patient recruitment, and streamlines regulatory compliance, ensuring faster, more accurate results. For Contract Research Organizations (CROs), this means unparalleled efficiency and a competitive edge in a rapidly evolving landscape. Consider the case of a leading CRO that integrated our AI solutions into their clinical trial process. By automating data management and predictive modeling, they achieved a 30% reduction in trial timelines and a 25% cost saving, ultimately accelerating the delivery of life-saving treatments to patients. Join us in celebrating innovation. Embrace the future of clinical trials with DST Technology's AI Accelerator—because every moment saved is a step closer to a healthier world. #InternationalClinicalTrialDay #AIinClinicalTrials #DSTTechnology #PharmaInnovation #CROefficiency

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. For too long, we've accepted inefficiency, complexity, and barriers to innovation as unavoidable challenges. It ends now. At Tilda, we envision a future where clinical trials are beacons of hope and innovation. A future where AI acts as an intelligent teammate, not just processing tasks but learning and evolving to obliterate administrative overhead. Where patient recruitment to study execution is seamless, and the burden on sites is dramatically reduced. We're not talking about incremental improvements - we're aiming for a 100-fold increase in trial efficiency, measured in quality, speed, and scale. Imagine a world where clinical trials are no longer hindered by complexity and inefficiency, but are instead powered by an AI-integrated system that anticipates needs, eliminates bottlenecks, and ensures unparalleled safety and efficacy. We're not just building software; we're crafting the future of healthcare itself. A future where patients can easily participate in trials, physicians readily engage in cutting-edge research, and life-saving drug development accelerates far beyond today's limits. This isn't just innovation; it's a moral imperative. The time for incremental change is over. The future of clinical trials is here, powered by AI, driven by empathy, and bringing new treatment options to patients. Welcome to the age of AI-integrated clinical trials. If you want to be part of this transformation, we invite you to follow Tilda CEO and Founder Ram Yalamanchili, and visit our website at www.tilda.bio.